Thrombin activatable fibrinolysis inhibitor and clot lysis time in women with recurrent miscarriage associated with the antiphospholipid syndrome

Fertility and Sterility

Volumn 94, Issue 6, 2010, Pages 2437-2440

  Martínez Zamora, M Angeles ^a   Creus, Montserrat ^a   Tassies, Dolors ^a   Bové, Albert ^a   Reverter, Juan Carlos ^a   Carmona, Francisco ^a   Balasch, Juan ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DNA POLYMORPHISM; FEMALE; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; SPONTANEOUS ABORTION;

ABORTION, HABITUAL; ADULT; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CARBOXYPEPTIDASE U; CASE-CONTROL STUDIES; FEMALE; FIBRINOLYSIS; HUMANS; PREGNANCY; TIME FACTORS;

EID: 78049265797     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2010.02.032     Document Type: Article

References (33)

1. K.A. Bremme Haemostatic changes in pregnancy Best Pract Res Clin Haematol 16 2003 153 168
2. B. Brenner Haemostatic changes in pregnancy Thromb Res 114 2004 409 414
3. F.E. Preston, F.R. Rosendaal, I.D. Walker, E. Briet, E. Berntorp, and J. Conard Increased fetal loss in women with heritable thrombophilia Lancet 348 1996 913 916
4. R. Rai Is miscarriage a coagulopathy? Curr Opin Obstet Gynecol 15 2003 265 268
5. M.M. Patnaik, T. Haddad, and C.T. Morton Pregnancy and thrombophilia Expert Rev Cardiovasc Ther 5 2007 753 765
6. S. Miyakis, M.D. Lockshin, T. Atsumi, D.W. Branch, R.L. Brey, and R. Cervera International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J Thromb Haemost 4 2006 295 306
7. J. Balasch, M. Creus, F. Fabregues, J.C. Reverter, F. Carmona, and D. Tassies Antiphospholipid antibodies and human reproductive failure Hum Reprod 11 1996 2310 2315
8. D. Vinatier, P. Dufour, M. Cosson, and J.L. Houpeau Antiphospholipid syndrome and recurrent miscarriages Eur J Obstet Gynecol Reprod Biol 96 2001 37 50
9. C.G. Mackworth-Young Antiphospholipid syndrome: multiple mechanisms Clin Exp Immunol 136 2004 393 401
10. S.S. Pierangeli, P.P. Chen, E. Raschi, S. Scurati, C. Grossi, and M.O. Borghi Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms Semin Thromb Hemost 34 2008 236 250
11. G. Espinosa, R. Cervera, J. Font, and Y. Shoenfeld Antiphospholipid syndrome: pathogenic mechanisms Autoimmunity Rev 2 2003 86 93
12. R. Forastiero, and M. Martinuzzo Prothombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome Lupus 17 2008 872 877
13. B.N. Bouma, and J.C. Meijers Thombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypectidase U) J Thromb Haemost 1 2003 1566 1574
14. R.F. Franco, M.G. Fagundes, J.C. Meijers, P.H. Reitsma, D. Lourenco, and V. Morelli Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis Haematologica 86 2001 510 517
15. M. Henry, H. Aubert, P.E. Morange, I. Nanni, M.C. Alessi, and L. Tiret Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled Blood 97 2001 2053 2058
16. J.L. Curnow, M.-C. Morel-Kopp, C. Roddie, M. Aboud, and C.M. Ward Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay J Thromb Haemost 5 2006 528 534
17. W. Wang, M.B. Boffa, L. Bajzar, J.B. Walker, and M.E. Nesheim A study of the mechanism of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor J Biol Chem 273 1998 27176 27181 (Pubitemid 28500426)
18. N. Folkeringa, F.J. Korteweg, N.J.G.M. Veeger, S. Middeldorp, K. Hamulyak, and M.H. Prins Thrombin activatable fibrinolysis inhibitor (TAFI) is not associated with fetal loss, a retrospective study Thromb Res 123 2009 511 514
19. H.M. Knol, N.J.G.M. Veeger, S. Middeldorp, K. Hamulyak, and J. Van der Meer High thrombin-activatable fibrinolysis inhibitor levels may protect against recurrent fetal loss J Thromb Haemost 7 2009 903 906
20. S. Masini, C. Ticconi, P. Gravina, M. Tomassini, A. Pietropolli, and V. Forte Thrombin-activatable fibrinolysis inhibitor polymorphisms and recurrent pregnancy loss Fertil Steril 92 2009 694 702
21. J.C. Gris, J.F. Schved, S. Neveu, P. Mares, P. Aguilar-Martinez, and D. Dupaigne Impaired fibrinolytic capacity and early recurrent spontaneous abortion BMJ 300 1990 1500
22. R. Rai, E. Tuddenham, M. Backos, S. Jivraj, S. El'Gaddal, and S. Choy Thromboelastography, whole-blood haemostasis and recurrent miscarriage Hum Reprod 12 2003 2540 2543
23. M. Creus, J.M. Calafell, S. Civico, F. Fabregues, F. Carmona, and J.A. Vanrell Materno-fetal immunogenetic disparity: the biological basis for in vitro fertilization treatment in patients with unexplained recurrent abortion? Am J Reprod Immunol 50 2003 420 426
24. J.T. Brandt, D.A. Triplett, B. Alving, and I. Scharrer Criteria the diagnosis of lupus anticoagulant: an update. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH Thromb Haemost 74 1995 1185 1190
25. A. Gils, M.C. Alessi, E. Browers, M. Peeters, P. Marx, and J. Leurs Development of a genotype 325-specific proCPU/TAFI ELISA Arterioscler Thromb Vasc Biol 23 2003 1122 1127
26. M.E. Meltzer, C.J. Doggen, P.G. de Groot, F.R. Rosendaal, and T. Lisman Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men Br J Haematol 145 2009 121 127
27. M.A. Martínez-Zamora, D. Tassies, F. Carmona, G. Espinosa, R. Cervera, and J.C. Reverter Thrombin activatable fibrinolysis inhibitor (TAFI) and clot lysis time (CLT) in pregnant patients with antiphospholipid syndrome (APS): relationship with pregnancy outcome and thrombosis Am J Reprod Immunol 62 2009 381 389
28. J.S. Levine, J. Rauch, and D.W. Branch Anti-phospholipid syndrome N Engl J Med 346 2002 752 763
29. F. Carmona, I. Lazaro, J.C. Reverter, D. Tassies, J. Font, and R. Cervera Impaired factor XIIa-dependent activation of fibrinolysis in treated antiphospholipid syndrome gestations developing late-pregnancy complications Am J Obstet Gynecol 194 2006 457 465
30. A. Sotiriadis, A. Makrigiannakis, T. Stefos, E. Paraskevaidis, and S.N. Kalantaridou Fibrinolytic defects and recurrent miscarriage: a systematic review and meta-analysis Obstet Gynecol 109 2007 1146 1155
31. T. Lisman, P.G. deGroot, J.C.M. Meijers, and F.R. Rosendaal Reduced plasma fibrinolytic potential is a risk for venous thrombosis Blood 105 2005 1102 1105
32. American College of Obstetricians and Gynecologists Management of recurrent early pregnancy loss. ACOG Practice Bulletin Int J Gynecol Obstet 78 2002 179 190
33. O.B. Christiansen, R. Steffensen, H.S. Nielsen, and K. Varming Multifactorial etiology of recurrent miscarriage and its scientific and clinical implications Gynecol Obstet Invest 66 2008 257 267